(lp0
S"Analytical Guide for Amicus Therapeutics, Inc. , Valley National Bancorp ... The USA Commerce - 20 hours ago Shares of Amicus Therapeutics, Inc.  dropped -3.03% to $7.03. During the trading on 03/14/2017, Company's stock ranged from $6.97 to $7.35."
p1
aS"Why Amicus Therapeutics, Inc. Jumped Higher Today Motley Fool - Mar 1, 2017 Amicus Therapeutics  ended the day up 17%, after the company's CEO John Crowley and his daughter Megan  were highlighted during President Donald Trump's address to Congress last night.The Unlikely Story Of How Amicus Therapeutics Came To Be - BenzingaAmicus Therapeutics, Inc.  Could Be The Force That Brings Change ... - Market Exclusive"
p2
aS'Amicus Therapeutics, Inc.  Upgraded by Zacks Investment Research to Hold Chaffey Breeze - 7 hours ago Amicus Therapeutics, Inc.  was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report released on Wednesday.Quarterly EPS Projection Of Amicus Therapeutics, Inc.  At $-0.37 - Stock ObserverAmicus Therapeutics, Inc.  loses confidence of 27 hedge fund managers - Post Analyst'
p3
aS'Amicus Therapeutics Launches Galafold in UK  Investopedia - Feb 28, 2017 Amicus Therapeutics Inc.  launched the first oral precision drug, Galafold , for treating Fabry disease in the United Kingdom.Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate ... - GlobeNewswire Amicus Therapeutics Inc.: Amicus Therapeutics to Present at Upcoming Investor ... - The Wall Street Transcript'
p4
aS'Amicus Therapeutics Launches Galafold  for Treatment of Fabry ... GlobeNewswire  - Feb 27, 2017 CRANBURY, N.J., Feb. 27, 2017  -- Amicus Therapeutics , a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in the&nbsp;...Amicus Therapeutics  Launches Galafold in the UK - StreetInsider.com'
p5
aS'Stock Spotlight: Zooming in on Shares of Amicus Therapeutics, Inc.  Davidson Register - 18 hours ago Investors are keeping a close eye on shares of Amicus Therapeutics, Inc. . The stock has a current six month price index of 0.99434.'
p6
aS'Traders Secrets on Kratos Defense &amp; Security Solutions, Inc. , Amicus ... StockNewsJournal - Mar 14, 2017 Amicus Therapeutics, Inc. , at its latest closing price of $7.25, it has a price-to-book ratio of 2.98, compared to an industry average at 3.98.'
p7
aS'Amicus Therapeutics Inc.  Soars 7.89% on February 27 Equities.com - Feb 27, 2017 Amicus Therapeutics Inc.  had a good day on the market for Monday February 27 as shares jumped 7.89% to close at $6.43.'
p8
aS'Amicus Therapeutics Inc.  Moves Higher on Volume Spike for March 03 Equities.com - Mar 3, 2017 Amicus Therapeutics Inc.  traded on unusually high volume on Mar. 03, as the stock gained 4.85% to close at $7.79. On the day, Amicus Therapeutics Inc. saw 5.65 million shares trade hands on 24,755 trades. Considering that the stock averages only&nbsp;...Insider Trading Activity Amicus Therapeutics, Inc.   COO Sold ... - Market ExclusiveIs It Time to go for Mast Therapeutics, Inc. , Amicus Therapeutics, Inc ... - StockNewsJournal'
p9
aS'Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium 2017 GlobeNewswire  - Feb 15, 2017 SAN DIEGO and CRANBURY, N.J., Feb. 14, 2017  -- Amicus Therapeutics , a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced new positive data analyses for the oral&nbsp;...Amicus Posts Positive Update for Migalastat  - Investopedia'
p10
a.